Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences announced that the Phase 3 PEAK trial results for bezuclastinib plus sunitinib in GIST have been selected for an oral presentation at the 2026 ASCO Annual Meeting. The presentation highlights the positive data supporting the combination therapy, following a New Drug Application submission under the FDA's Real-Time Oncology Review program in March 2026.
Key figures
- Drug Name
- bezuclastinib
- Phase Of Trial
- Phase 3
- Nda status
- submitted under Real-Time Oncology Review (RTOR)
- Nda submission date
- March 2026
- Asco abstract number
- 11500
- Upcoming trial phase
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.